Matinas Biopharma Holdings Inc

-0.03 (-2.63%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)238.37M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.53 Million
Adjusted EPS-$0.02
See more estimates
10-Day MA$1.14
50-Day MA$0.98
200-Day MA$1.02
See more pivots

Matinas Biopharma Holdings Inc Stock, ASE:MTNB

1545 Route 206 South, Suite 302, Bedminster, New Jersey 07921-9999
United States of America
Phone: +1.908.443.1860
Number of Employees: 20


Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B, and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded by Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.